REGROTON
LOE ApproachingNDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REGROTON is an oral tablet NDA approved in 1964 by Sanofi with unknown mechanism of action and pharmacologic class. The drug's specific indications and therapeutic area are not documented in available data. Patient population and clinical utility cannot be determined without additional information.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating potential downsizing of brand team and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REGROTON currently supports zero linked job openings, reflecting its mature stage and approaching LOE. Career opportunities are likely contracting, with focus shifting from growth to transition management and generic defense strategies.
Brand ManagerField Sales Representative
Worked on REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.